Invizius

Invizius develops treatments to prevent life threatening inflammation during dialysis.

Edinburgh, UK—Founded 2018

£3.7MTotal raised

Invizius is an Edinburgh based biotech company developing treatments to mitigate inflammatory responses in dialysis patients. The firm originated as a spin out from the University of Edinburgh.

Founders

Andy Herbert

CTO

Andy brings biotech founding and board-level experience from roles at AH-Bio and Invizius. He previously held scientific advisory and research positions at Gemini Therapeutics and the University of Edinburgh.

Richard Boyd

CEO

Richard brings biotech and medtech operating experience from leadership roles at Invizius and VueKlar Cardiovascular. He currently focuses on early-stage biotech and medtech venture development.